Narrative review reveals the diagnostic utility of molecular alterations across sarcoma subtypes, highlighting the need for genetic markers to improve differential diagnosis and targeted therapies.
INTRODUCTION: Sarcomas are a very rare (<1% solid tumors) and highly heterogeneous group of malignant neoplasms with over 100 subtypes. The complexity and rarity of this disease pose serious troubles with differential diagnosis with the use of traditional methods (histology and immunohistochemistry); hence, there is more and more interest in the genetic background of sarcoma development and prognosis in search for genetic markers that might allow the improvement of the diagnostic process, disease prognosis, and monitoring. AREAS COVERED: This review provides a brief summary of current knowledge of the diagnostic relevance of the molecular background of sarcoma. It includes descriptions of traditional and novel methods for genetic alteration assessments, as well as perspectives on the diagnostic or prognostic use of certain genetic markers. EXPERT OPINION: The origin of most sarcomas remains not fully understood, even with rapid advances in high-precision molecular techniques. There is an ongoing need for further studies aimed to uncover the complete mechanisms behind the development and progression of these rare yet dangerous tumors, especially in light of improved differential diagnosis and targeted treatment options, including early phase clinical trials.
No takes yet. Share an insight, caveat, or question.
Wiśniewska et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: